Prognostic value of serum cystatin C and N-terminal pro b-type natriuretic peptide in patients with acute heart failure

被引:53
作者
Ignacio Perez-Calvo, Juan [1 ]
Jose Ruiz-Ruiz, Francisco [1 ]
Javier Carrasco-Sanchez, Francisco [2 ]
Luis Morales-Rull, Jose [3 ]
Manzano-Fernandez, Sergio [4 ]
Galisteo-Almeda, Luis [5 ]
Pascual-Figal, Domingo [4 ]
机构
[1] Univ Zaragoza, Hosp Clin Univ Lozano Blesa, Fac Med, Dept Internal Med, E-50009 Zaragoza, Spain
[2] Hosp Juan Ramon Jimenez, Serv Med Interna, Huelva, Spain
[3] Hosp Arnau Vilanova, Serv Med Interna, Lerida, Spain
[4] Hosp Univ Virgen de la Arrixaca, Serv Cardiol, Murcia, Spain
[5] Hosp Juan Ramon Jimenez, Serv Bioquim Clin & Lab, Huelva, Spain
关键词
Acute heart failure; Biomarkers; Cystatin C; NTpro-BNP; GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; RENAL-FUNCTION; ELDERLY PERSONS; CARDIOVASCULAR RISK; EJECTION FRACTION; CREATININE; MORTALITY; METAANALYSIS; BIOMARKERS;
D O I
10.1016/j.ejim.2012.06.002
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background: Cystatin C (CysC) is a good prognostic marker in heart failure. However, there is not much information of CysC combined with other biomarkers in acute heart failure (AHF). Aim: To assess prognostic value of CysC and N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients hospitalized for AHF with no apparent deterioration of renal function. Design: Prospective, multicenter, observational study. Methods: CysC and NTpro-BNP were measured in patients consecutively admitted with a diagnosis of AHF. Patients with, NTpro-BNP concentration above 900 pg/mL and serum creatinine below 1.3 mg/dL, were included for statistical analysis. End-point of the study was all-cause mortality during a 12-month follow-up. Results: 526 patients with AHF and NTpro-BNP concentration above 900 pg/mL were included in the study. From this group, 367 patients (69.8%) had serum creatinine below 1.3 mg/dL. Receiver operating characteristic (ROC) curves were used to determine the best cut-off value for CysC. Patients with a concentration of CsyC above 1.25mg/dL had a 37.8% mortality rate, vs. 13.6% for those below cut-off (p<0.001). After Cox proportional hazard model, age, CysC, low total cholesterol and HF with preserved ejection fraction remained significantly associated with all-cause mortality during one-year follow-up. Conclusions: In AHF and normal or slightly impaired renal function, performance of CysC may be superior to NT-proBNP. Hence, CysC may be the preferred biomarker in the assessment of patients with AHF and slightly impaired renal function. (C) 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:599 / 603
页数:5
相关论文
共 28 条
[1]
Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care [J].
Alehagen, Urban ;
Dahlstrom, Ulf ;
Lindahl, Tomas L. .
EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (04) :354-360
[2]
Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure [J].
Arimoto, T ;
Takeishi, Y ;
Niizeki, T ;
Takabatake, N ;
Okuyama, H ;
Fukui, A ;
Tachibana, H ;
Nozaki, N ;
Hirono, O ;
Tsunoda, Y ;
Miyashita, T ;
Shishido, T ;
Takahashi, H ;
Koyama, Y ;
Kubota, I .
JOURNAL OF CARDIAC FAILURE, 2005, 11 (08) :595-601
[3]
Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population With Heart Failure and Preserved Versus Reduced Ejection Fraction [J].
Ather, Sameer ;
Chan, Wenyaw ;
Bozkurt, Biykem ;
Aguilar, David ;
Ramasubbu, Kumudha ;
Zachariah, Amit A. ;
Wehrens, Xander H. T. ;
Deswal, Anita .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (11) :998-1005
[4]
Usefulness of Cystatin C and Prognosis Following Admission for Acute Heart Failure [J].
Campbell, Catherine Y. ;
Clarke, William ;
Park, Haeseong ;
Haq, Nowreen ;
Barone, Bethany B. ;
Brotman, Daniel J. .
AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (03) :389-392
[5]
Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis [J].
Dharnidharka, VR ;
Kwon, C ;
Stevens, G .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 40 (02) :221-226
[6]
Renal function, neurohormonal activation, and survival in patients with chronic heart failure [J].
Hillege, HL ;
Girbes, ARJ ;
de Kam, PJ ;
Boomsma, F ;
de Zeeuw, D ;
Charlesworth, A ;
Hampton, JR ;
van Veldhuisen, DJ .
CIRCULATION, 2000, 102 (02) :203-+
[7]
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients [J].
Januzzi, JL ;
van Kimmenade, R ;
Lainchbury, J ;
Bayes-Genis, A ;
Ordonez-Llanos, J ;
Santalo-Bel, M ;
Pinto, YM ;
Richards, M .
EUROPEAN HEART JOURNAL, 2006, 27 (03) :330-337
[8]
Prognostic Value of Cystatin C on Admission in Heart Failure With Preserved Ejection Fraction [J].
Javier Carrasco-Sanchez, Francisco ;
Galisteo-Almeda, Luis ;
Paez-Rubio, Inmaculada ;
Javier Martinez-Marcos, Francisco ;
Camacho-Vazquez, Crescencio ;
Ruiz-Frutos, Carlos ;
Pujol-De la Llave, Emilio .
JOURNAL OF CARDIAC FAILURE, 2011, 17 (01) :31-38
[9]
Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP [J].
Lassus, Johan ;
Harjola, Veli-Pekka ;
Sund, Reijo ;
Siirilae-Waris, Krista ;
Melin, John ;
Peuhkurinen, Keijo ;
Pulkki, Kari ;
Nieminen, Markku S. .
EUROPEAN HEART JOURNAL, 2007, 28 (15) :1841-1847
[10]
Cystatin C: a step forward in assessing kidney function and cardiovascular risk [J].
Lassus, Johan ;
Harjola, Veli-Pekka .
HEART FAILURE REVIEWS, 2012, 17 (02) :251-261